This company has been marked as potentially delisted and may not be actively trading. Vital Therapies (VTL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VTL vs. BIOA, VIRI, WHWK, PYRGF, ELYM, ATNM, OSTX, NBRV, AADI, and EGRXShould you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), OS Therapies (OSTX), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), and Eagle Pharmaceuticals (EGRX). Vital Therapies vs. Its Competitors BioAge Labs Virios Therapeutics Whitehawk Therapeutics PyroGenesis Canada Eliem Therapeutics Actinium Pharmaceuticals OS Therapies Nabriva Therapeutics Aadi Bioscience Eagle Pharmaceuticals BioAge Labs (NASDAQ:BIOA) and Vital Therapies (NASDAQ:VTL) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership. Does the media favor BIOA or VTL? In the previous week, BioAge Labs had 10 more articles in the media than Vital Therapies. MarketBeat recorded 10 mentions for BioAge Labs and 0 mentions for Vital Therapies. BioAge Labs' average media sentiment score of 0.17 beat Vital Therapies' score of 0.00 indicating that BioAge Labs is being referred to more favorably in the media. Company Overall Sentiment BioAge Labs Neutral Vital Therapies Neutral Do institutionals & insiders have more ownership in BIOA or VTL? 15.5% of Vital Therapies shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by company insiders. Comparatively, 33.9% of Vital Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has stronger earnings & valuation, BIOA or VTL? Vital Therapies has lower revenue, but higher earnings than BioAge Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge Labs$3.86M42.23-$71.11MN/AN/AVital TherapiesN/AN/A-$41.47MN/AN/A Is BIOA or VTL more profitable? BioAge Labs' return on equity of -25.39% beat Vital Therapies' return on equity.Company Net Margins Return on Equity Return on Assets BioAge LabsN/A -25.39% -23.22% Vital Therapies N/A -235.33%-182.35% SummaryBioAge Labs beats Vital Therapies on 5 of the 8 factors compared between the two stocks. Get Vital Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTL vs. The Competition Export to ExcelMetricVital TherapiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.19M$779.54M$5.68B$9.81BDividend YieldN/A4.84%3.79%4.11%P/E RatioN/A1.2131.0825.11Price / SalesN/A26.44466.21115.16Price / CashN/A19.5637.4059.05Price / Book3.116.599.096.18Net Income-$41.47M-$4.71M$3.26B$265.11M Vital Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTLVital TherapiesN/A$0.90-1.6%N/A-29.5%$38.19MN/A0.0010BIOABioAge LabsN/A$4.44+0.5%N/AN/A$159.17MN/A0.00N/ANews CoverageVIRIVirios TherapeuticsN/A$4.86+0.2%$5.00+2.9%+2,505.9%$93.59MN/A-18.005Gap DownWHWKWhitehawk TherapeuticsN/A$1.77+0.6%N/AN/A$83.38M$27.78M11.0640PYRGFPyroGenesis CanadaN/A$0.29-1.5%N/A-58.3%$53.72M$9.14M-4.7890Gap UpELYMEliem TherapeuticsN/A$1.70+17.2%N/A-71.8%$50.58MN/A-3.219High Trading VolumeATNMActinium Pharmaceuticals2.9506 of 5 stars$1.62-2.4%$4.00+146.9%-13.3%$50.54MN/A-1.1730News CoveragePositive NewsShort Interest ↓Analyst RevisionOSTXOS Therapies2.2731 of 5 stars$1.72-0.6%$18.00+946.5%-41.8%$48.33MN/A-2.00N/ANews CoverageUpcoming EarningsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi Bioscience0.5107 of 5 stars$1.74-0.6%$1.67-4.2%+11.7%$42.97M$25.07M-0.7640EGRXEagle PharmaceuticalsN/A$3.19flatN/AN/A$41.43M$257.55M0.00100 Related Companies and Tools Related Companies BIOA Competitors VIRI Competitors WHWK Competitors PYRGF Competitors ELYM Competitors ATNM Competitors OSTX Competitors NBRV Competitors AADI Competitors EGRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTL) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vital Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vital Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access